Home > Insider Trading > Filing (0001209191-19-056093)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1396814	Pacira Biosciences Inc.	PCRX	Pharmaceutical Preparations (2834)	510619477

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1545439	Bullaro Lauren Riker	C/O Pacira Biosciences, Inc. 5 Sylvan Way, Suite 300 Parsippany NJ 07054	Vice President, Finance	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-11-11	4,820	$10.34	15,460	No	4	M	Direct
Common Stock	Acquisiton	2019-11-11	180	$10.81	15,640	No	4	M	Direct
Common Stock	Disposition	2019-11-11	5,000	$43.59	10,640	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2019-11-11	4,820	$0.00	4,820	$10.34
Common Stock	Stock Option (Right to Buy)	Disposition	2019-11-11	180	$0.00	180	$10.81

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
18,180		2021-05-10	No	4	M	Direct
29,820		2022-06-05	No	4	M	Direct

Footnotes

Includes 598 shares of common stock acquired under the issuer's employee stock purchase plan in June 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.50 to $43.96, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option vested and became exercisable as to 25% of the option shares on May 2, 2012 and vested as to the remaining shares in successive equal monthly installments over the subsequent 36 months.
The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months.